4682-94-4

Basic information

• Product Name: furan-2-yl(4-hydroxyphenyl)methanone
• CAS NO: 4682-94-4
• Molecular Formula: C₁₁H₈O₃
• Molecular Weight: 188.1794
• Mol File: 4682-94-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 366.3°C at 760 mmHg
• Flash Point: 175.3°C
• Density: 1.264g/cm³
• Vapor Pressure: 7.02E-06mmHg at 25°C
• Refractive Index: 1.59
• CAS DataBase Reference: furan-2-yl(4-hydroxyphenyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: furan-2-yl(4-hydroxyphenyl)methanone(4682-94-4)
• EPA Substance Registry System: furan-2-yl(4-hydroxyphenyl)methanone(4682-94-4)

Safety Data

• Hazardous Substances Data: 4682-94-4(Hazardous Substances Data)

Upstream product

• 100-07-2 4-methoxy-benzoyl chloride 
• 100-09-4 4-methoxybenzoic acid 
• 15970-74-8 furan-2-yl(4-methoxyphenyl)methanone 
• 88-14-2 2-furanoic acid 
• 527-69-5 2-furancarbonyl chloride 
• 100-66-3 methoxybenzene 
• 7446-70-0 aluminium trichloride 
• 98-95-3 nitrobenzene 
• 108-95-2 phenol 
• 93-99-2 benzoic acid phenyl ester 
• 106-41-2 4-bromo-phenol 
• 2948-14-3 furan-2-carboxylic acid phenyl ester 

Downstream Products

• 15970-74-8 furan-2-yl(4-methoxyphenyl)methanone 
• 21493-98-1 (4-ethoxy-phenyl)-[2]furyl ketone 

Relevant articles and documents

Synthesis and biological activities of new halophenols

A series of new halophenols were synthesized, and their structures were established on the basis of 1H, 13C NMR and mass spectral data. All of the prepared compounds were screened for their in vitro protein tyrosine kinase (PTK) and vascular smooth muscle cell (VSMC) proliferation inhibitory activity. Twelve halophenols showed significant PTK inhibitory activity, most of them exhibited stronger activities than that of genistein, a positive reference compound. Several halophenols also displayed moderate VSMC proliferation inhibitory activity, compound 8c showed higher activity than that of tetrandrine, a positive reference compound. The preliminary structure-activity relationships of these compounds were investigated and discussed. The results provided a foundation for the action mechanism study and further structure optimization of the halophenols.

Synthesis and structure-activity relationship for new series of 4-phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase

We discovered a new series of 4-phenoxyquinoline derivatives as potent and selective inhibitors of the platelet-derived growth factor receptor (PDGFr) tyrosine kinase. We researched the highly potent and selective inhibitors on the basis of both PDGFr and epidermal growth factor receptor (EGFr) inhibitory activity. First, we found a compound, Ki6783 (1), which inhibited PDGFr autophosphorylation at 0.13 μM, but it did not inhibit EGFr autophosphorylation at 100 μM. After extensive explorations, we found the two desired compounds, Ki6896 (2) and Ki6945 (3), which are substituted by benzoyl and benzamide at the 4-position of the phenoxy group on 4-phenoxyquinoline, respectively. These inhibitory activities were 0.31 and 0.050 μM, respectively, but neither of them inhibited EGFr autophosphorylation at 100 μM. We further investigated the profile of both compounds toward various tyrosine and serine/threonine kinases. The three compounds specifically inhibited PDGFr rather than the other kinases.